Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Disarib + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Disarib||BCL2 inhibitor 17||Disarib is a small molecule inhibitor of BCL2, which targets the BH1 domain of BCL2, thereby interfering with the interaction between BCL2 and BAK, and subsequently, leading to apoptosis (PMID: 28223017).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||B-cell adult acute lymphocytic leukemia||not applicable||Disarib + Paclitaxel||Preclinical - Cell culture||Actionable||In a preclinical study, Taxol (paclitaxel) efficacy was enhanced when combined with Disarib, resulting in greater cell death compared to either agent alone in B-cell acute lymphocytic leukemia cells in culture (PMID: 27693384).||27693384|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|